Vicore Pharma (Buy, TP: SEK41.00) - Intends to start clinical trial in Covid-19 patients
Vicore Pharma announced that it intends to initiate a phase II trial investigating C21 in patients with Covid-19. Results are expected in around four months. The stock rose sharply on the news, likely as a result of the great need for a potential treatment against the ongoing pandemic. We see sound scientific rationale behind the decision to investigate the potential effect of C21 in patients with Covid-19. We have not changed our view on the stock on the news and reiterate our BUY and target price SEK41.Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.